Tardive Dyskinesia and intellectual disability: An examination of demographics and topography in adults with dual diagnosis and atypical antipsychotic use

Research in Developmental Disabilities

Volumn 31, Issue 3, 2010, Pages 750-759

  Fodstad, Jill C ^a   Bamburg, Jay W ^b   Matson, Johnny L ^a   Mahan, Sara ^a   Hess, Julie A ^a   Neal, Daniene ^a   Holloway, Jodie ^b  

^a LOUISIANA STATE UNIVERSITY   (United States)

^b Pinecrest Supports and Services Center   (United States)

Author keywords

Adults; Atypical antipsychotic; ID; MEDS; Tardive dyskinesia

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIHYPERTENSIVE AGENT; ANXIOLYTIC AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT;

ADULT; ARTICLE; CLINICAL ASSESSMENT TOOL; DEMOGRAPHY; DEVELOPMENTAL DISORDER; DRUG USE; FEMALE; HUMAN; INTELLECTUAL IMPAIRMENT; MAJOR CLINICAL STUDY; MALE; MOTOR DYSFUNCTION; QUALITY OF LIFE; TARDIVE DYSKINESIA; TOPOGRAPHY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; DEPRESSIVE DISORDER; DYSKINESIA, DRUG-INDUCED; FEMALE; HUMANS; MALE; MENTAL RETARDATION; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PSYCHOTIC DISORDERS; PSYCHOTROPIC DRUGS; RESIDENTIAL FACILITIES; RISK FACTORS; SEVERITY OF ILLNESS INDEX; STEREOTYPIC MOVEMENT DISORDER; YOUNG ADULT;

EID: 77950691038     PISSN: 08914222     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ridd.2010.01.017     Document Type: Article

References (66)

1. Advokat C.D., Mayville E.A., Matson J.L. Side effect profiles of atypical antipsychotics, typical antipsychotics, or no psychotropic medications in persons with mental retardation. Research in Developmental Disabilities 2000, 21:75-84.
2. Aman M.G., Singh N.N. Psychopharmacology of the developmental disabilities 1988, Springer-Verlag, Berlin.
3. American Psychiatric Association. (2000). Diagnostic and Statistical Manual of Mental Disorders-Text Revision (4th ed.). Washington, D.C.: Author.
4. Baumeister A., Sevin J.A. Pharmacologic control of aberrant behavior in the mentally retarded: Toward a more rational approach. Neuroscience and Biobehavioral Reviews 1990, 14:253-262.
5. Casey D.E. Tardive dyskinesia and atypical antipsychotic drugs. Schizophrenia Research 1999, 35:S61-S66.
6. Casey D.E. Neuroleptic-induced extrapyramidal syndromes and tardive dyskinesia. Schizophrenia 1995, 546-565. Blackwell, Oxford, England. S. Hirsch, D.R. Weinberger (Eds.).
7. Caykoylu A., Ekinci O., Yilmaz E. Resolution of risperidone-induced tardive dyskinesia with a switch to aropiprazole monotherapy. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2009, 33:571-572.
8. Cherry K.E., Paclawskyj T., Matson J.L. Psychopathology in older adults with severe and profound mental retardation. American Journal of Mental Retardation 1997, 101:445-458.
9. Cheung P.P.P., Siu A.M.H. A comparison of patterns of sensory processing in children with and without developmental disabilities. Research in Developmental Disabilities 2009, 30:1468-1480.
10. Danki D., Dilbaz N., Okay I.T. Severe extrapyramidal symptoms due to valproate plus low dose olanzapine: A case report. Klinik Psikofarmakoloji Bulteni 2006, 16:42-46.
11. Dawson J.E., Matson J.L., Cherry K. An analysis of maladaptive behaviors in persons with autism, PDD-NOS and mental retardation. Research in Developmental Disabilities 1998, 19:439-448.
12. Deb S., Thomas M., Bright C. Mental disorder in adults with intellectual disability. I: Prevalence of functional psychiatric illness among a community-based population aged between 16 and 64 years. Journal of Intellectual Disability Research 2001, 45:495-505.
13. de Leon J., Greenlee B., Barber J., Sabaawi M., Singh N.N. Practical guidelines for the use of new generation antipsychotic drugs (expect clozapine) in adult individuals with intellectual disabilities. Research in Developmental Disabilities 2009, 30:613-669.
14. Gathercole S.E., Alloway T.P. Working memory deficits in neurodevelopmental disorders. Journal of Child Psychology and Psychiatry 2006, 47:4-15.
15. Gharabawi G.M., Bossie C.A., Lasser R.A., Turkoz I., Rodriguez S., Chouinard G. Abnormal Involuntary Movement Scale (AIMS) and Extrapyramidal Symptom Rating Scale (ESRS): Cross-scale comparison in assessing tardive dyskinesia. Schizophrenia Research 2005, 77(2):119-128.
16. Hardiman S., Guerin S., Fitzsimons E. A comparison of the social competence of children with moderate intellectual disability in inclusion versus segregated school settings. Research in Developmental Disabilities 2009, 30:397-407.
17. Haw C., Stubbs J. A survey of off-label prescribing for inpatients with mild intellectual disability and mental illness. Journal of Intellectual Disability Research 2005, 49:858-864.
18. Holden B., Gitlesen J.P. Psychotropic medication in adults with mental retardation: Prevalence, and prescriptive practices. Research in Developmental Disabilities 2004, 25:509-521.
19. Holden B., Gitlesen J.P. The relationship between psychiatric symptomatology and motivation of challenging behavior: A preliminary study. Research in Developmental Disabilities 2008, 29:408-413.
20. Holden B., Gitlesen J.P. The overlap between psychiatric symptoms and challenging behaviour: A preliminary study. Research in Developmental Disabilities 2009, 30:210-218.
21. Kane J.M., Jeste D.V., Barnes T.E., Casey D.E., Cole J.O., Davis J.M., et al. Tardive Dyskinesia: A task force report of the american psychiatric association 1992, American Psychiatric Association, Washington, DC.
22. Kane J.M., Woerner M., Lieberman J. Tardive Dyskinesia: Prevalence, incidence, and risk factors. Journal of Clinical Psychopharmacology 1988, 8:525-565.
23. Kaufman D.M. Clinical neurology for psychiatrists 2007, Sonders-Elsevier, Philadelphia, PA. 6th ed.
24. Lancioni G.E., Singh N.N., O'Reilly M.F., Sigafoos J. An overview of behavioral strategies for reducing hand-related stereotypies of persons with severe to profound intellectual and multiple disabilities: 1995-2007. Research in Developmental Disabilites 2009, 30:20-43.
25. Leonard H., Hoheneck D. Metabolic side effects of the atypical antipsychotic olanzapine in an inpatient population of adults with developmental disabilities. Mental Health Aspects of Developmental Disabilities 2006, 9:18-22.
26. Leucht S., Wahlbeck K., Hamann J., Kissling W. New generation antipsychotics versus low-potency conventional antipsychotics: A systematic review and meta-analysis. The Lancet 2003, 361:1581-11581.
27. Matson, J. L. (1995a). The Diagnostic Assessment for the Severely Handicapped revised (DASH-II). Baton Rouge, LA: Disability Consultants, LLC. http://disabilityconsultants.org/.
28. Matson, J. L. (1995b). The Matson Evaluation of Social Skills for Individuals with Severe Retardation (MESSIER). Baton Rouge, LA: Disability Consultants, LLC. http://disabilityconsultants.org/.
29. Matson, J. L. (1997). The Assessment for Dual Diagnosis (ADD). Baton Rouge, LA: Disability Consultants, LLC. http://disabilityconsultants.org/.
30. Matson, J. L. (1998). Matson Evaluation of Drug Side-effects (MEDS). Baton Rouge, LA: Disability Consultants, LLC. http://disabilityconsultants.org/.
31. Matson J.L., Bamburg J.W. Reliability of the assessment of dual diagnosis (ADD). Research in Developmental Disabilities 1998, 19:89-95.
32. Matson J.L., Bamburg J., Smalls Y., Smiroldo B.B. Evaluating behavioral techniques in training functional independent living skills to individuals with severe and profound mental retardation. Behavior Modification 1997, 21:533-543.
33. Matson J.L., Bielecki J.M., Mayville S.B., Matson M.L. Psychopharmacology research for individuals with mental retardation: Methodological issues and suggestions. Research in Developmental Disabilities 2003, 24:149-157.
34. Matson J.L., Boisjoli J.A. Restraint procedures and challenging behaviors in intellectual disability: An analysis of causative factors. Journal of Applied Research in Intellectual Disabilities 2009, 22:111-117.
35. Matson J.L., Fodstad J.C., Rivet T.T. The convergent and divergent validity of the Matson Evaluation of Drug Side Effects and the Dyskinesia Identification System Condensed User Scale (DISCUS). Journal of Intellectual and Developmental Disabilities 2008, 33:337-344.
36. Matson J.L., Hamilton M., Duncan D., Bamburg J., Smiroldo B., Anderson S., et al. Characteristics of stereotypic movement disorder and self-injurious behavior as assessed with the Diagnostic Assessment for the Severely Handicapped (DASH-II). Research in Developmental Disabilities 1997, 18:457-469.
37. Matson J.L., Laud R.B. Assessment and treatment of psychopathology among people with developmental delays. Handbook of intellectual and developmental disabilities 2007, 507-539. Springer, New York, NY. J.W. Jacobson, J.A. Mulick, J. Rojahn (Eds.).
38. Matson J.L., Mayville E.A., Bamburg J.W., Eckholdt C.S. An analysis of side-effect profiles of anti-seizure medications in persons with intellectual disability using the Matson Evaluation of Drug Side Effects (MEDS). Journal of Intellectual and Developmental Disabilities 2001, 26:283-295.
39. Matson J.L., Mayville E.A., Bielecki J., Barnes W.H., Bamburg J.W., Baglio C.S. Reliability of the Matson Evaluation of Drug Side Effects scale (MEDS). Research in Developmental Disabilities 1998, 19:501-506.
40. Matson J.L., Neal D. Psychotropic medication use for challenging behaviors in persons with intellectual disabilities: An overview. Research in Developmental Disabilities 2009, 30:572-586.
41. Matson J.L., Rivet T.T., Fodstad J.C. Matson Evaluation of Drug Side-Effects (MEDS) profiles of selective serotonin reuptake inhibitors (SSRI) in adults with intellectual disability. Journal of Developmental and Physical Disabilities 2009, 21:57-68.
42. Matson J.L., Rivet T.T., Fodstad J.C. Psychometric properties and participant characteristics for person with intellectual disability using the Matson Evaluation of Drug Side-effects (MEDS). Journal of Developmental and Physical Disabilities 2008, 20:243-255.
43. Matson J.L., Rivet T.T., Fodstad J.C. Matson Evaluation of Drug Side-Effects (MEDS) profiles in adults with intellectual disability, tardive dyskinesia, and akathesia. Journal of Developmental and Physical Disabilities 2008, 20:283-295.
44. Matson J.L., Rivet T.T., Fodstad J.C. Atypical antipsychotic adjustments and side- effects over time in adults with intellectual disability, tardive dyskinesia, and akathisia. Journal of Developmental and Physical Disabilities 2009, 10.1007/s10882-009-9179-z.
45. Matson J.L., Smalls Y., Hampff A., Smiroldo B.B., Anderson S.J. A comparison of behavioral techniques to teach functional independent living skills to individuals with severe and profound mental retardation. Behavior Modification 1998, 2:298-306.
46. Matson J.L., Wilkins J. Antipsychotic drugs for aggression in intellectual disability. The Lancet 2008, 371:9-10.
47. Matson J.L., Smiroldo B.B., Bamburg J.W. The relationship of social skills to psychopathology for individuals with severe and profound mental retardation. Journal of Intellectual Disabilities Research 1998, 23:137-145.
48. Myrbakk E., von Tetzchner S. Psychiatric disorders and behavior problems in people with intellectual disability. Research in Developmental Disabilities 2008, 29:316-332.
49. Meltzer H.Y. Atypical antipsychotic drugs have their merits. The Lancet 2009, 373:1007.
50. Quinn J., Meagher D., Murphy P., Kinsella A., Mullaney J., Waddington J.L. Vulnerability to involuntary movements over a lifetime trajectory of schizophrenia approaches 100%, in association with executive (frontal) dysfunction. Schizophrenia Research 2001, 49:79-87.
51. Rinck C. Epidemiology and psychoactive medication. Psychotropic medications and developmental disabilities: The international consensus handbook 1998, 31-44. The Ohio State University Nisonger Center, Ohio. S. Reiss, M.G. Aman (Eds.).
52. Rijcken C.A.W., Monster T.B.M., Brouwers J.R.B.J., de Jong-van den Berg L.T.W. Chlorpromazine equivalents versus defined daily doses: How to compare antipsychotic drug doses?. Journal of Clinical Psychopharmacology 2003, 23(6):657-659.
53. Ross E., Oliver C. The assessment of mood in adults who have severe or profound mental retardation. Clinical Psychology Review 2003, 23:225-245.
54. Soenen S., Van Berckelaer-Onnes I., Scholte E. Patterns of intellectual, adaptive, and behavioral functioning in individuals with mild mental retardation. Research in Developmental Disabilities 2009, 30:433-444.
55. Sparrow, S., Balla, D., & Cicchetti, D. V. (1984). The Vineland Adaptive Behavior Scales (survey form) Circle Pines, MN: American Guidance Service.
56. Sprague R.L., Kalachnik J.E., Shaw K.M. Psychometric properties of the Dyskinesia Identification System: Condensed User Scale (DISCUS). Mental Retardation 1989, 27(3):141-148.
57. Sprague R.L., Kalachnik J.E. Reliability and a total score cutoff for the Dyskinesia Identification System: Condensed User Scale (DISCUS) with mentally ill and mentally retarded populations. Psychopharmacology Bulletin 1991, 27:51-58.
58. Tenneij N.H., Didden R., Stolker J.J., Koot H.M. Markers for aggression in inpatient treatment facilities for adults with mild to borderline intellectual disability. Research in Developmental Disabilities 2009, 30:1248-1257.
59. Tonge B.J., Einfeld S.L. Psychopathology and intellectual disability: The Australian child to adult longitudinal study. International Review of Research in Mental Retardation 2003, 26:61-91.
60. Tyrer P., Kendall T. Atypical antipsychotics drugs have their merits: Authors' reply. The Lancet 2009, 373:1007-1008.
61. Tyrer P., Oliver-Africano P.G., Ahmed Z., Bouras N., Cooray S., Deb S., et al. Risperidone, haloperidol, and placebo in the treatment of aggressive challenging behaviour in patients with intellectual disability: A randomized controlled trial. Lancet 2008, 371:57-63.
62. Valdovinos M.G., Schroeder S.R., Kim G. Prevalence and correlates of psychotropic medication use among adults with developmental disabilities: 1970-2000. International Review of Research in Mental Retardation 2003, 26:175-220.
63. van Os J., Fahy T., Jones P., Harvey I., Toone B., Murray R. Tardive dyskinesia: Who is at risk?. Acta Psychiatrica Scandinavica 2007, 96:206-216.
64. Van der Molen M., Van Luit J.E.H., Jongmans M.J., Van der Molen M.W. Memory profiles in children with mild intellectual disabilities: Strengths and weaknesses. Research in Developmental Disabilities 2009, 30:1237-1247.
65. Woerner M.G., Alvir J.M.J., Saltz B.L., Lieberman J.A., Kane J.M. Prospective study of tardive dyskinesia in the elderly: Rates and risk factors. American Journal of Psychiatry 1998, 155:1521-1528.
66. World Health Organization (WHO) Collaborating Centre for Drug Statistics Methodology. (2007). ATC/DDD Index 2007 Retrieved October 2007, from http://www.whocc.no/atcddd/.